NG Biotech is a French innovative biotech company developing & manufacturing novel in vitro diagnostic tools for Therapy Monitoring at the Point of Care (Onsite). NG Biotech patented platform is rapid, mobile and connected; it allows to analyze a direct sample as finger prick blood in 5 minutes and to communicate the result.

The company, founded by pioneers of the rapid test industry, has developed a proprietary patented immunoassay platform enabling the development of quantitative and multiplex point of care diagnostics. The platform can be adapted to detect or monitor any kind of antibody, antigen, pathogen, parasite, hormone , drug… The tests are then associated to wireless mobile readers. Results are obtained in few minutes from a single drop of blood (or any other type of sample) and can be communicated to any server or cloud for data sharing and management.

NG Biotech already sells a range of CE marked rapid tests Worldwide and is planning to be CFR21 compliant in 2017. Product validations are performed in comparison to laboratory standard reference methods as Elisa or HPLC. The company is ISO 9001 and 13485 certified.

Current production capacity is of more than 5 million tests per year. The company has the experience and plans to rapidly scale-up.

At NG Biotech they support partners’ Innovation meeting their screening and monitoring needs; they develop new solutions for their applications. Targeted areas are m-Health, Companion and Medical Diagnostics; they also cover Animal Health, Agriculture and Biodefense among others. They put their know how and expertise in product development, manufacturing and product registration at service.

VISION
To become one of the global leaders in rapid, mobile and connected diagostics

 

MISSIONS
- To leverage Healthcare value and improve Global Health with a new generation of « multiplex », « quantitative » and « connected » rapid diagnostic tests
- To capitalize on an experienced team (+30 years in RDTs)